The 2008 guidelines of the American College of Rheumatology (ACR), updated in 2012, do not recommend the use of anti-TNF-α in pharmacologically untreated chronic hepatitis B and treated with considerable damage to the liver (Child class-Pugh B and C). The gene discussed is TNF; the disease is chronic hepatitis B virus infection.